Elizabeth Yeu Lin - Dec 31, 2021 Form 3 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Dec 31, 2021
Transactions value $
$0
Form type
3
Date filed
1/4/2022, 08:09 PM
Previous filing
Jun 25, 2021
Next filing
Jun 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TARS Employee Stock Option (right to buy) Dec 31, 2021 Common Stock 2.02K $2.01 Direct F1
holding TARS Employee Stock Option (right to buy) Dec 31, 2021 Common Stock 33.4K $10.99 Direct F2
holding TARS Employee Stock Option (right to buy) Dec 31, 2021 Common Stock 4.54K $10.99 Direct F3
holding TARS Employee Stock Option (right to buy) Dec 31, 2021 Common Stock 5.2K $34.72 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). 504 of the option shares vest and become exercisable on April 16, 2021. The remainder of the option shares vest and become exercisable in 36 equal monthly installments beginning May 16, 2021.
F2 Option granted under the Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on September 1, 2020.
F3 Option granted under the Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.
F4 Option granted under the Plan. The option shares vest and become exercisable on March 2, 2022.

Remarks:

Exhibit 24 - Power of Attorney